{
  "doc_id": "Best-Vitelliform-Macular-Dystrophy",
  "doc_filename": "Best-Vitelliform-Macular-Dystrophy.pdf",
  "top_entities": [
    {
      "name": "Best vitelliform macular dystrophy",
      "mention_count": 1,
      "entity_type": "disease"
    },
    {
      "name": "retinitis pigmentosa 30",
      "mention_count": 1,
      "entity_type": "disease"
    }
  ],
  "file_size_bytes": 1646,
  "file_size_human": "1.6 KB",
  "file_extension": ".pdf",
  "pdf_title": "(anonymous)",
  "pdf_author": "(anonymous)",
  "pdf_page_count": 1,
  "pdf_creation_date": "2026-01-07T22:25:17",
  "doi": null,
  "doi_url": null,
  "document_type_code": "DLA",
  "document_type_name": "Disease Landscape Analysis",
  "document_type_group": "Disease Landscape Analysis",
  "classification_confidence": 0.85,
  "title": "Best Vitelliform Macular Dystrophy (BVMD) Clinical Overview",
  "short_description": "Clinical overview of Best Vitelliform Macular Dystrophy, a hereditary macular degeneration affecting approximately 1 in 10,000 individuals with typical onset between ages 5-10.",
  "long_description": "This document provides essential clinical information about Best Vitelliform Macular Dystrophy (BVMD), a relatively common form of inherited macular degeneration. The document outlines key epidemiological data including prevalence rates, typical age of onset patterns, gender distribution, and ethnic populations affected. BVMD is characterized as affecting approximately 1 in 10,000 individuals with no gender preference, typically manifesting between ages 5-10 years, though onset can vary. The condition has been documented across diverse ethnic backgrounds including European, African, and Hispanic populations, indicating its broad genetic distribution.",
  "document_date": "2026-01-07T22:25:17",
  "document_date_source": "pdf_metadata",
  "extraction_timestamp": "2026-02-04T17:25:41.954731"
}